Annie Appleseed Project
  • Home
  • About Us
    • Board of Directors
    • Blog Post
    • Newsletters
    • Updates – Magazine Articles, Radio Shows, Etc.
    • Testimonials
  • Links
  • Cancer Clinics
  • Meeting Summaries
    • Cam Conference 2023
    • Cam Conference 2020
    • Summaries From Meetings
  • Info by Cancer Types
    • Alternative Cancer Therapies >
      • laetrile-vit-b17-amygdalin-from-apricot-kernels-induces-apoptosis-and-causes-cell-cycle-arrest-in-cancer-cells-an-updated-review
    • Handouts
  • Vlog
    • 2018 AAPR Conference
  • Exhibitors
    • The Gonzalez Protocol
    • Beautiful Organics
    • American Biosciences
    • Doctor's Biome
    • Nathan Crane Movies
    • United Patients Group
    • EarthSave Miami
    • Agape Healing Arts
    • Keep Me Safe Organics
  • Contact Us
  • Donate
  • Giving Tuesday

SERIOUS DRUG TOXICITIES RECOGNIZED DURING POSTMARKETING SURVEILLANCE

NEW YORK (Reuters Health)

The rate of serious adverse effects in drugs newly approved by the US Food and Drug Administration (FDA) is so high that physicians should view any new drug as a black box, researchers suggest in the May 1st, 2002 issue of the Journal of the American Medical Association.

However, many of the causes of past drug withdrawals are now being caught in preclinical trials, Drs. Robert J. Temple and Martin H. Himmel, of the FDA, comment in a journal editorial.

Investigators led by Dr. Karen E. Lasser, of Cambridge Hospital and Harvard Medical School in Massachusetts, identified 56 new drugs–representing 10.2% of those approved by the FDA between 1975 and 1999–that were given a new black box warning in the Physicians’ Desk Reference or were withdrawn from the market. Half of the withdrawals occurred within 2 years after the drug’s introduction, while half of new black box warnings were issued within 7 years.

Dr. Lasser’s group proposes that the FDA raise its threshold for approving new drugs when safe and effective alternatives exist or if the targeted condition is benign. They also recommend that physicians avoid using newly approved drugs when possible, and when that is not feasible, that patients be monitored for hepatic, hematologic and cardiac toxicity.

In an interview with Reuters Health, Dr. Lasser expounded on this theme. “More studies have to be done before drugs are released and millions of patients are exposed,” she said.

She reminded physicians that patients in clinical trials are not representative of the population that may ultimately be exposed to the drug, such as elderly individuals, children and those with comorbid conditions. “The testing needs to be superior to what is out there now,” she emphasized.

Drs. Temple and Himmel, based in Rockville, Maryland, defend the FDA’s handling of new drugs. For example, they point out, rare adverse effects are unlikely to be uncovered in premarketing trials. In addition, many labeling changes are associated with antineoplastic agents and antiviral drugs, all of which are expected to have substantial toxicity.

They note that the FDA has updated its requirements of manufacturers in light of past adverse events. Drugs are now evaluated thoroughly for their effect on cardiac repolarization, hepatotoxicity, and ability to inhibit hepatic enzymes that interact with other drugs.

“If there is sound reason to use a recently approved drug, the physician need not deny the patient this treatment,” they write.

May 2002 JAMA  Ann’s NOTE: And yet ASCO did not seriously examine harms until around 2016.​

Annie Appleseed Project
​

Picture
This site complies with the HONcode standard for trustworthy health information: verify here.
Picture
Annie Appleseed Project - Sign Up Today!

* required

*





*



Email & Social Media Marketing by VerticalResponse
WHO WE ARE   I   PRIVACY POLICY   I   ADVERTISING POLICY   I   ARCHIVES   I   IN HONOR/MEMORY OF

​Remember: We are NOT Doctors and have NO medical training. DISCLAIMER: The information provided is for educational purposes only. It is not meant to diagnose or treat any health condition and is not a replacement for treatment by a healthcare provider. This article or site may contain copyrighted material, the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of health, political, human rights, economic, democratic, and social justice issues, etc. We believe this constitutes a “fair use” of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed an interest in receiving the included information for research and educational purposes. For more information go to: Cornell University Law School.
​© Annie Appleseed Project. All rights reserved.
  • Home
  • About Us
    • Board of Directors
    • Blog Post
    • Newsletters
    • Updates – Magazine Articles, Radio Shows, Etc.
    • Testimonials
  • Links
  • Cancer Clinics
  • Meeting Summaries
    • Cam Conference 2023
    • Cam Conference 2020
    • Summaries From Meetings
  • Info by Cancer Types
    • Alternative Cancer Therapies >
      • laetrile-vit-b17-amygdalin-from-apricot-kernels-induces-apoptosis-and-causes-cell-cycle-arrest-in-cancer-cells-an-updated-review
    • Handouts
  • Vlog
    • 2018 AAPR Conference
  • Exhibitors
    • The Gonzalez Protocol
    • Beautiful Organics
    • American Biosciences
    • Doctor's Biome
    • Nathan Crane Movies
    • United Patients Group
    • EarthSave Miami
    • Agape Healing Arts
    • Keep Me Safe Organics
  • Contact Us
  • Donate
  • Giving Tuesday